Literature DB >> 15870133

Influence of human body composition on serum peak thyrotropin (TSH) after recombinant human TSH administration in patients with differentiated thyroid carcinoma.

Maria Grazia Castagna1, Aldo Pinchera, Alessandro Marsili, Monica Giannetti, Eleonora Molinaro, Paola Fierabracci, Lucia Grasso, Furio Pacini, Ferruccio Santini, Rossella Elisei.   

Abstract

OBJECTIVES: In this study, we evaluated the influence of height, weight, body mass index (BMI), body surface area, and body composition [total lean body mass (LBM) and fat body mass] on serum peak TSH levels obtained after recombinant human (rh)TSH. Furthermore, to verify whether the serum peak TSH influenced the efficacy of radioiodine ((131)I), we compared the rate of thyroid remnant ablation according to the patients' BMI. PATIENTS: We studied 105 patients with differentiated thyroid carcinoma who underwent rhTSH stimulation test. Serum TSH measurements were performed before and 24, 48, and 72 h after rhTSH administration. We also compared the rate of thyroid remnant ablation among 70 differentiated thyroid carcinoma patients with different BMI.
RESULTS: The serum peak TSH after rhTSH was significantly lower in overweight and obese subjects compared with normal-weight subjects (92.1 +/- 41.8, 82.4 +/- 24.2, and 112.7 +/- 46.3 microU/ml, respectively; P = 0.01) and in males compared with females (74.6 +/- 22.3 and 105.0 +/- 43.0 microU/ml, respectively; P = 0.0002). By univariate analysis, serum peak TSH was negatively related to weight, height, body surface area, BMI, LBM, and fat body mass, but only LBM was independently associated with serum peak TSH levels. Although it was confirmed that overweight and obese patients had a lower serum peak TSH, the rate of ablation did not differ among normal-weight, overweight, and obese patients.
CONCLUSIONS: With this study we demonstrated that LBM is the only parameter independently associated with serum peak TSH after rhTSH administration. However, the serum peak TSH does not influence the rate of (131)I remnant ablation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15870133     DOI: 10.1210/jc.2005-0534

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Clinical utility of an ultrasensitive thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer: can the stimulation test be avoided in patients with an intermediate recurrence risk?

Authors:  A Flores-Rebollar; I Pérez-Díaz; S Lagunas-Bárcenas; B García-Martínez; R Rivera-Moscoso; R Fagundo-Sierra
Journal:  Acta Otorhinolaryngol Ital       Date:  2018-06       Impact factor: 2.124

2.  Age modifies the response to recombinant human thyrotropin.

Authors:  Rebecca Over; Hala Nsouli-Maktabi; Kenneth D Burman; Jacqueline Jonklaas
Journal:  Thyroid       Date:  2010-10-18       Impact factor: 6.568

Review 3.  Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer.

Authors:  Joanna Klubo-Gwiezdzinska; Kenneth D Burman; Douglas Van Nostrand; Mihriye Mete; Jacqueline Jonklaas; Leonard Wartofsky
Journal:  Endocr Pract       Date:  2013 Jan-Feb       Impact factor: 3.443

4.  Analysis of Clinical Factors for the Determination of Optimal Serum Level of Thyrotropin After Recombinant Human Thyroid-Stimulating Hormone Administration.

Authors:  Seung Hyun Son; Sang-Woo Lee; Ji-Hoon Jung; Choon-Young Kim; Do-Hoon Kim; Shin Young Jeong; Byeong-Cheol Ahn; Jaetae Lee
Journal:  Nucl Med Mol Imaging       Date:  2015-09-01

5.  Indirect Basal Metabolism Estimation in Tailoring Recombinant Human TSH Administration in Patients Affected by Differentiated Thyroid Cancer: A Hypothesis-Generating Study.

Authors:  Agnese Barnabei; Lidia Strigari; Agnese Persichetti; Roberto Baldelli; Laura Rizza; Claudia Annoscia; Rosa Lauretta; Giovanni Cigliana; Maddalena Barba; Aurora De Leo; Marialuisa Appetecchia; Francesco Torino
Journal:  Front Endocrinol (Lausanne)       Date:  2018-02-15       Impact factor: 5.555

6.  Strong Neck Accumulation of 131I Is a Predictor of Incomplete Low-Dose Radioiodine Remnant Ablation Using Recombinant Human Thyroid-Stimulating Hormone.

Authors:  Keisuke Enomoto; Yoshiharu Sakata; Kazuyuki Izumi; Yukinori Takenaka; Miki Nagai; Kazuya Takeda; Yukie Enomoto; Atsuhiko Uno
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.